Sai Life Sciences
- Market cap
- ₹ 29,699 Cr.
- P/E
- 85.9x
- P/B
- 11.9x
- 52-week range
- 783.85 – 1,697
- ROE
- 15%
- ROCE
- 20%
- Dividend yield
- 0%
- Debt / equity
- 0.12
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sai Life Sciences Limited is an India-based company. The Company is a contract research, development, and manufacturing organization (CRDMO). It offers a range of tailor-made services for biotech firms or global pharma company requirements. Its services include integrated drug discovery services, drug metabolism and pharmacokinetics (DMPK), synthetic & medicinal chemistry, biology services, general toxicology, genotoxicity, and computational chemistry services. It also offers chemistry, manufacturing and controls (CMC) services which include route scouting, process familiarization, optimization & development, analytical method development & validation, process safety evaluation, stability studies, and early phase scale-up. Its discovery biology facility provides exploratory biology services to the expanding array of start-up and biotech companies in the Boston area and to companies in North America.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sai Life Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)85.9 against a typical 34.3: pricier than most peers (1st = cheapest).186th of 220
- Sales growth+11.7% against a typical +15.6% from a year earlier.110th of 197
- Profit growth+21.7% against a typical +18.9% from a year earlier.78th of 160
- Share price, 3 months+13.8% against a typical 0%.53rd of 200
- Size₹ 29,699.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).19th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA to AA- by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA | Stable | 26 Feb 2026 |
| India Ratings | IND AA-; IND A1+ | Positive | 14 Aug 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 26 Feb 2026 | Reaffirmed | [ICRA]AA | — | ICRA | ₹ 768.6 Cr. | |
| 14 Aug 2025 | Rating action | IND AA- | — | India Ratings | ₹ 769 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 6 Aug 2026 | Financial Results | To consider and approve the Un Audited financial results for the period ended Jun 30, 2026 |
| 14 May 2026 | Financial Results | To consider and approve the Audited Financial Results (Standalone & Consolidated) for the fourth quarter and year ended March 31, 2026 |
| 5 Feb 2026 | Financial Results | To consider and approve the Un-audited Financial Results for the third quarter and nine months ended December 31, 2025. |
| 6 Nov 2025 | Financial Results | To consider and approve the Un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | To consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended Jun 30, 2025 |
| 13 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| Profit before tax | 53 | 76 | −18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Tax % | 25% | 26% | −25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 40 | 56 | −14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS in Rs | — | — | — | — | 2.59 | 4.24 | 2.9 | 4 | 4.75 | 4.92 | 3.45 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 24%
- 3 Years
- 22%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 42%
- 3 Years
- 226%
- TTM
- 51%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 9%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sai Life Sciences | ₹ 1,497.00 | ₹ 29,699 Cr. | 85.9x | 11.9x | 15% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Kanumuri Ranga Raju
- Executive Chairman of the Board
- Krishnam Raju Kanumuri
- Chief Executive Officer, Managing Director
- Sivaramakrishnan Chittor
- Additional Whole-Time Director and Chief Financial Officer
- Runa Karan
- Chief Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.